Current recommendations for Helicobacter pylori therapies in a world of evolving resistance

Gut Microbes

Volumn 4, Issue 6, 2013, Pages

  Mégraud, Francis ^a,b  

^a Laboratoire de Bactériologie   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Antibiotics; Clarithromycin; Empiric treatment; Eradication; Mutation; Quadruple therapy; Tailored treatment; Triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; RIFAMPICIN; TETRACYCLINE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BISMUTH;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL CLEARANCE; BACTERIAL SURVIVAL; BACTERIUM CULTURE; CLINICAL TRIAL (TOPIC); HELICOBACTER INFECTION; HUMAN; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PRACTICE GUIDELINE; REVIEW; DRUG EFFECT; EMPIRIC TREATMENT; EMPIRICAL RESEARCH; ERADICATION; HELICOBACTER PYLORI; METABOLISM; MUTATION; QUADRUPLE THERAPY; STOMACH MUCOSA; TAILORED TREATMENT; TREATMENT OUTCOME; TRIPLE THERAPY;

ANTIBIOTICS; CLARITHROMYCIN; EMPIRIC TREATMENT; ERADICATION; MUTATION; QUADRUPLE THERAPY; TAILORED TREATMENT; TRIPLE THERAPY;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; BISMUTH; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; EMPIRICAL RESEARCH; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; TREATMENT OUTCOME;

EID: 84888420981     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.25930     Document Type: Review

References (80)

1. Bazzoli F, Zagari R, Fossi S, et al. Efficacy and toler-ability of a short-term low-dose triple therapy for eradication of Helicobacter pylori. Am J Gastroenterol 1993; 104:40A
2. Lamouliatte HC, Cayla R, Mégraud F, Zerbib F, Stablo M, Bouchard S, et al. Amoxicillin-clarithromycin-omeprazole: the best therapy for Helicobacter pylori infection. Acta Gastroenterol Belg 1993; 56:A140
3. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996; 1:138-44 PMID:9398894 http://dx.doi.org/10.1111/j.1523-5378.1996. tb00027.x
4. Lind T, Mégraud F, Unge P, Bayerdörffer E, O'morain C, Spiller R, Veldhuyzen Van Zanten S, Bardhan KD, Hellblom M, Wrangstadh M, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116:248-53 PMID:9922303 http://dx.doi.org/10.1016/S0016-5085(99)70119-8
5. European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41:8-13 PMID:9274464 http://dx.doi.org/10.1136/gut.41.1.8
6. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13:1-12 PMID:9737564 http://dx.doi.org/10.1111/j.1440-1746.1998.tb00537.x
7. Coelho LG, León-Barúa R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol 2000; 95:2688-91 PMID:11051336 http://dx.doi.org/10.1016/S0002-9270(00)01967-5
8. Borody TJ, George LL, Brandl S, Andrews P, Lenne J, Moore-Jones D, Devine M, Walton M. Helicobacter pylori eradication with doxycycline-metronidazole-bis-muth subcitrate triple therapy. Scand J Gastroenterol 1992; 27:281-4 PMID:1589705 http://dx.doi.org/10.3109/00365529209000075
9. Meyer-Rosberg K, Scott DR, Rex D, Melchers K, Sachs G. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 1996; 111:886-900 PMID:8831583 http://dx.doi.org/10.1016/S0016-5085(96)70056-2
10. Sachs G, Meyer-Rosberg K, Hong C, Melchers K, Scott D. Biologie de Helicobacter pylori dans l'estomac. La lettre de l'Infectiologue 1997; 12:16-20.
11. Goddard A F, Jessa MJ, Barrett DA, Shaw PN, Idström J P, Cederberg C, Spiller RC. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clar-ithromycin in human gastric juice. Gastroenterology 1996; 111:358-67 PMID:8690200 http://dx.doi.org/10.1053/gast.1996.v111.pm8690200
12. Matysiak-Budnik T, Heyman M, Candalh C, Lethuaire D, Mégraud F. In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier: effect of Helicobacter pylori. J Antimicrob Chemother 2002; 50:865-72 PMID:12461005 http://dx.doi.org/10.1093/jac/dkf219
13. Nakamura M, Spiller RC, Barrett DA, Wibawa JI, Kumagai N, Tsuchimoto K, Tanaka T. Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithro-mycin triple therapy. Helicobacter 2003; 8:294-9 PMID:12950601 http://dx.doi.org/10.1046/j.1523-5378.2003.00156.x
14. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20:280-322 PMID:17428887 http://dx.doi.org/10.1128/CMR.00033-06
15. Versalovic J, Shortridge D, Kibler K, Griffy M V, Beyer J, Flamm RK, Tanaka SK, Graham DY, Go MF. Mutations in 23S rRNA are associated with clarithro-mycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40:477-80 PMID:8834903
16. Occhialini A, Urdaci M, Doucet-Populaire F, Bébéar CM, Lamouliatte H, Mégraud F. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997; 41:2724-8 PMID:9420046
17. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53:1374-84 PMID:15306603 http://dx.doi.org/10.1136/gut.2003.022111
18. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995; 39:107-11 PMID:7695290 http://dx.doi.org/10.1128/AAC.39.1.107
19. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003; 47:3942-4 PMID:14638505 http://dx.doi.org/10.1128/AAC.47.12.3942-3944.2003
20. Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, Santarelli L, Arancio F, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14:1339-43 PMID:11012480 http://dx.doi.org/10.1046/j.1365-2036.2000.00846.x
21. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007; 39:1001-5 PMID:17889627 http://dx.doi.org/10.1016/j.dld.2007.06.016
22. Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999; 43:1497-9 PMID:10348780
23. Suzuki S, Suzuki H, Nishizawa T, Kaneko F, Ootani S, Muraoka H, Saito Y, Kobayashi I, Hibi T. Past rifampi-cin dosing determines rifabutin resistance of Helicobacter pylori. Digestion 2009; 79:1-4 PMID:19142036 http://dx.doi.org/10.1159/000191204
24. Trieber CA, Taylor DE. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol 2002; 184:2131-40 PMID:11914344 http://dx.doi.org/10.1128/JB.184.8.2131-2140.2002
25. Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013; 18:206-14 PMID:23241101 http://dx.doi.org/10.1111/hel.12031
26. Ribeiro ML, Gerrits MM, Benvengo YH, Berning M, Godoy A P, Kuipers EJ, Mendonça S, van Vliet AH, Pedrazzoli J Jr., Kusters JG. Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP. FEMS Immunol Med Microbiol 2004; 40:57-61 PMID:14734187 http://dx.doi.org/10.1016/S0928-8244(03)00277-3
27. Chung JW, Lee GH, Jeong JY, Lee SM, Jung JH, Choi KD, Song HJ, Jung HY, Kim JH. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol 2012; 27:493-7 PMID:21793912 http://dx.doi.org/10.1111/j.1440-1746.2011.06874.x
28. Suzuki RB, Almeida CM, Sperança MA. Absence of Helicobacter pylori high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. BMC Gastroenterol 2012; 12:49 PMID:22594560 http://dx.doi.org/10.1186/1471-230X-12-49
29. Gerrits MM, Schuijffel D, van Zwet AA, Kuipers EJ, Vandenbroucke-Grauls CM, Kusters JG. Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother 2002; 46:2229-33 PMID:12069978 http://dx.doi.org/10.1128/AAC.46.7.2229-2233.2002
30. Mendz GL, Mégraud F. Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol 2002; 10:370-5 PMID:12160635 http://dx.doi.org/10.1016/S0966-842X(02)02405-8
31. Glupczynski Y, Broutet N, Cantagrel A, Andersen L P, Alarcon T, López-Brea M, Mégraud F. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21:549-52 PMID:12172749 http://dx.doi.org/10.1007/s10096-002-0757-6
32. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini G F, Gisbert J P, Graham DY, Rokkas T, et al.; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. Gut 2012; 61:646-64 PMID:22491499 http://dx.doi.org/10.1136/gutjnl-2012-302084
33. Novo Y, Gavinet AM, Megraud F, Bebear C. Susceptibility of Campylobacter pylori to nitroimid-azole compounds in vitro. P 165-167 In: Megraud F, Lamouliatte H (Eds) Gastroduodenal pathology and Campylobacter pylori. Excerpta Medica ICS847, 1989. Amsterdam.
34. Mattila J, Männistö PT, Mäntylä R, Nykänen S, Lamminsivu U. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemother 1983; 23:721-5 PMID:6870221 http://dx.doi.org/10.1128/AAC.23.5.721
35. Adamsson I, Nord CE, Lundquist P, Sjöstedt S, Edlund C. Comparative effects of omeprazole, amoxy-cillin plus metronidazole versus omeprazole, clarithro-mycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother 1999; 44:629-40 PMID:10552979 http://dx.doi.org/10.1093/jac/44.5.629
36. Sjölund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 2003; 139:483-7 PMID:13679325 http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00011
37. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen L P, Goossens H, Glupczynski Y; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62:34-42 PMID:22580412 http://dx.doi.org/10.1136/gutjnl-2012-302254
38. Björkholm B, Sjölund M, Falk PG, Berg OG, Engstrand L, Andersson DI. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc Natl Acad Sci U S A 2001; 98:14607-12 PMID:11717398 http://dx.doi.org/10.1073/pnas.241517298
39. Glupczynski Y, Mégraud F, Lopez-Brea M, Andersen L P. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20:820-3 PMID:11783701 http://dx.doi.org/10.1007/s100960100611
40. Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, Uemura N, Katsuyama T, Fukuda Y, Haruma K, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007; 45:4006-10 PMID:17942652 http://dx.doi.org/10.1128/JCM.00740-07
41. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V, Menegatti M, Tampieri A, Perna F, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17:719-26 PMID:12641522 http://dx.doi.org/10.1046/j.1365-2036.2003.01461.x
42. Wang G, Wilson TJ, Jiang Q, Taylor DE. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 2001; 45:727-33 PMID:11181351 http://dx.doi.org/10.1128/AAC.45.3.727-733.2001
43. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772-81 PMID:17170018 http://dx.doi.org/10.1136/gut.2006.101634
44. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808-25 PMID:17608775 http://dx.doi.org/10.1111/j.1572-0241.2007.01393.x
45. Kawai T, Yamagishi T, Yagi K, Kataoka M, Kawakami K, Sofuni A, Itoi T, Sakai Y, Moriyasu F, Osaka Y, et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol 2008; 23(Suppl 2):S171-4 PMID:19120893 http://dx.doi.org/10.1111/j.1440-1746.2008.05408.x
46. Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ, Hsu YC, Tseng CH, et al.; Taiwan Helicobacter Consortium. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68:450-6 PMID:23099849 http://dx.doi.org/10.1093/jac/dks407
47. Fiorini G, Vakil N, Zullo A, Saracino IM, Castelli V, Ricci C, Zaccaro C, Gatta L, Vaira D. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2013; 11:507-10 PMID:23267869 http://dx.doi.org/10.1016/j.cgh.2012.12.007
48. Oleastro M, Ménard A, Santos A, Lamouliatte H, Monteiro L, Barthélémy P, Mégraud F. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 2003; 41:397-402 PMID:12517879 http://dx.doi.org/10.1128/JCM.41.1.397-402.2003
49. Rüssmann H, Adler K, Haas R, Gebert B, Koletzko S, Heesemann J. Rapid and accurate determination of genotypic clarithromycin resistance in cultured Helicobacter pylori by fluorescent in situ hybridization. J Clin Microbiol 2001; 39:4142-4 PMID:11682543 http://dx.doi.org/10.1128/JCM.39.11.4142-4144.2001
50. Cambau E, Allerheiligen V, Coulon C, Corbel C, Lascols C, Deforges L, Soussy CJ, Delchier JC, Megraud F. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009; 47:3600-3607 PMID:19759218 http://dx.doi.org/10.1128/JCM.00744-09
51. Wermeille J, Cunningham M, Dederding J P, Girard L, Baumann R, Zelger G, Buri P, Metry JM, Sitavanc R, Gallaz L, et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin Biol 2002; 26:216-9 PMID:11981460
52. Hirschowitz BI, Haber MM. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Pharmacol Ther 2001; 15:87-103 PMID:11136282 http://dx.doi.org/10.1046/j.1365-2036.2001.00876.x
53. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metaboliz-ers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70:484-92 PMID:11719736 http://dx.doi.org/10.1067/mcp.2001.119721
54. Demir K, Ormeci A, Emrence Z, Gokturk S, Baran B, Mutlauay Soyer O, et al. Effect of genotypic differences in CYP2C19 and on cure rates for Helicobacter pylori infection by triple therapy with different proton pump inhibitors. DDW 2013; 2013:a1915.
55. Perri F, Clemente R, Festa V, Quitadamo M, Conoscitore P, Niro G, Ghoos Y, Rutgeerts P, Andriulli A. Relationship between the results of pre-treat-ment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol 1998; 30:146-50 PMID:9675647
56. Broutet N, Marais A, Lamouliatte H, de Mascarel A, Samoyeau R, Salamon R, Mégraud F. cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia. J Clin Microbiol 2001; 39:1319-22 PMID:11283049 http://dx.doi.org/10.1128/JCM.39.4.1319-1322.2001
57. Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mégraud F. Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17:99-109 PMID:12492738 http://dx.doi.org/10.1046/j.1365-2036.2003.01396.x
58. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronida-zole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377:905-13 PMID:21345487 http://dx.doi.org/10.1016/S0140-6736(11)60020-2
59. Gisbert J P, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44:313-25 PMID:20054285
60. Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez- Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert J P. Nonbismuth quadruple (concomitant) therapy: empirical and tai lored efficacy versus standard triple therapy for clar- ithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter 2012; 17:269-76 PMID:22759326 http://dx.doi.org/10.1111/j.1523-5378.2012.00947.x
61. Gisbert J P, Calvet X. Update on non-bismuth qua druple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5:23-34 PMID:22457599 http://dx.doi.org/10.2147/CEG.S25419
62. Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18:129-34 PMID:23121338 http://dx.doi.org/10.1111/hel.12017
63. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378:507-14 PMID:21777974 http://dx.doi.org/10.1016/S0140-6736(11)60825-8
64. Gisbert J P, Pérez-Aisa A, Bermejo F, Castro-Fernández M, Almela P, Barrio J, Cosme A, Modolell I, Bory F, Fernández-Bermejo M, et al.; H. pylori Study Group of the Asociación Española de Gastroenterología (Spanish Gastroenterology Association). Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol 2013; 47:130-5 PMID:22647827 http://dx.doi.org/10.1097/MCG.0b013e318254ebdd
65. Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, Chou Y P, Hu ML, Tai WC, Chiu KW, Chiou SS, et al. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter 2012; 17:216-23 PMID:22515360 http://dx.doi.org/10.1111/j.1523-5378.2012.00937.x
66. Di Caro S, Fini L, Daoud Y, Grizzi F, Gasbarrini A, De Lorenzo A, Di Renzo L, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18:5669-78 PMID:23155306 http://dx.doi.org/10.3748/wjg.v18.i40.5669
67. Wu C, Chen X, Liu J, Li MY, Zhang ZQ, Wang ZQ. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-anal-ysis. Helicobacter 2011; 16:131-8 PMID:21435091 http://dx.doi.org/10.1111/j.1523-5378.2011.00826.x
68. Murakami K, Okimoto T, Kodama M, Tanahashi J, Fujioka T, Ikeda F, Muraoka H, Takigawa M, Saika T, Hasegawa M, et al. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother 2009; 53:3097-9 PMID:19380599 http://dx.doi.org/10.1128/AAC.01552-08
69. Murakami K, Furuta T, Ando T, Nakajima T, Inui Y, Oshima T, Tomita T, Mabe K, Sasaki M, Suganuma T, et al.; For the Japan GAST Study Group. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. [Epub ahead of print]. J Gastroenterol 2013 PMID:23307042 http://dx.doi.org/10.1007/s00535-012-0731-8
70. Chang WL, Kao CY, Wu CT, Huang AH, Wu JJ, Yang HB, Cheng HC, Sheu BS. Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan. Helicobacter 2012; 17:210-5 PMID:22515359 http://dx.doi.org/10.1111/j.1523-5378.2012.00935.x
71. Asaoka D, Nagahara A, Matsuhisa T, Takahashi SI, Tokunaga K, Kawai T, Kawakami K, Suzuki H, Suzuki M, Nishizawa T, et al. Trends of second-line eradication therapy for Helicobacter pylori in Japan: A multicenter study in the Tokyo metropolitan area. Helicobacter 2013 PMID:23773231
72. Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, et al. Effects of different dosing schedules of amoxicillin on the eradication rates of Helicobacter pylori by triple therapy with a proton pump inhibitor, amoxicillin, and either clarithromycin or metronida-zole. DDW 2013; 2013: a245.
73. Gisbert J P, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012; 35:941-7 PMID:22372560 http://dx.doi.org/10.1111/j.1365-2036.2012.05053.x
74. D'Elios MM, Silvestri E, Emmi G, Barnini T, Prisco D. Helicobacter pylori: usefulness of an empirical fourth-line rifabutin-based regimen. Expert Rev Gastroenterol Hepatol 2012; 6:437-9 PMID:22928895 http://dx.doi.org/10.1586/egh.12.32
75. Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Ikuma M, Shirai N. The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori. Hepatogastroenterology 2010; 57:1314-9 PMID:21410079
76. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25:155-68 PMID:17229240 http://dx.doi.org/10.1111/j.1365-2036.2006.03179.x
77. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32:1069-79 PMID:21039671 http://dx.doi.org/10.1111/j.1365-2036.2010.04457.x
78. Realdi G, Dore M P, Piana A, Atzei A, Carta M, Cugia L, Manca A, Are BM, Massarelli G, Mura I, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999; 4:106-12 PMID:10382124 http://dx.doi.org/10.1046/j.1523-5378.1999.99002.x
79. Koletzko S, Jones NL, Goodman KJ, Gold B, Rowland M, Cadranel S, Chong S, Colletti RB, Casswall T, Elitsur Y, et al.; H pylori Working Groups of ESPGHAN and NASPGHAN. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011; 53:230-43 PMID:21558964
80. Abdullahi M, Annibale B, Capoccia D, Tari R, Lahner E, Osborn J, Leonetti F, Severi C. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008; 18:1450-4 PMID:18443890 http://dx.doi.org/10.1007/s11695-008-9477-z